Financial Daily from THE HINDU group of publications
Wednesday, Oct 27, 2004
Financial Daily from THE HINDU group of publications Wednesday, Oct 27, 2004 |
||
|
|
||
|
Corporate Results
-
Pharmaceuticals Dabur Pharma turnover, PBT up in Q2 Our Bureau
New Delhi , Oct. 26 DABUR Pharma Ltd has recorded a turnover of Rs 129.9 crore for the first six months ended September 30, a growth of 14.9 per cent over the corresponding previous period. Profit before tax grew by 10.2 per cent from Rs 10 crore to Rs 11.1 crore. During the second quarter, the company posted 18.3 per cent growth in turnover, up from Rs 60.1 crore to Rs 71.1 crore, while profit before tax grew by 12.1 per cent from Rs 4.8 crore to Rs 5.4 crore. "The bulk drug business recorded a growth of 60 per cent in sales. The formulations business has grown in countries where we have received regulatory approvals, which had to be reapplied for after the demerger," said Mr Ajay Vij, COO. Dr Anand Burman, Chairman, said: "We have completed the process of demerger from DIL and the stock is now listed on the NSE and the BSE." He added that the company has initiated phase II clinical trials of a New Chemical Entity (NCE), DRF7295, and a New Drug Delivery System, TNP. "The results have been encouraging. Overall, we have been able to surpass industry growth rates yet again through our strategic focus and expansion of our international operations. The company is on track to file its first ANDA in the US during this year."
More Stories on : Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|